Neuronetics Inc (STIM)
NASDAQ:STIM
Earnings Data
Report Date
May 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.21Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated meaningful commercial progress from the Greenbrook integration (strong pro forma revenue growth, treatment volume expansion, improved referral network, NeuroStar capital momentum, and positive Q4 operating cash flow) alongside clear near-term challenges (gross margin compression from clinic mix, ongoing legal inquiry, expected negative operating cash flow in FY2026 before H2 recovery, and reimbursement uncertainty for new therapies). Management provided guidance for growth (2026 revenue $160M–$166M, midpoint >9% YoY), a path to reduced operating expenses and positive operating cash flow in the back half of 2026, and strategic optionality via the COMPASS collaboration—overall the positives around growth, integration progress, and improving cash metrics were emphasized, tempered by notable execution, margin, and regulatory risks.Company Guidance
Strong Pro Forma Revenue Growth
Total revenue for Q4 was $41.8M (reported +86% YoY driven by acquisition); adjusted pro forma Q4 revenue grew 23% versus prior year, reflecting combined NeuroStar + Greenbrook momentum.
Clinic and Treatment Volume Expansion
Clinic revenue was $23.5M in Q4, an adjusted pro forma increase of 37%; full-year clinic revenue grew 28% pro forma. Total treatment volume was up 18% YoY in Q4 and treatment utilization increased ~11%.
NeuroStar Capital Momentum
Shipped 49 NeuroStar systems in Q4 (vs. 46 in prior-year quarter); U.S. system revenue $4.4M, +15% pro forma; system average selling price was above target for the fourth consecutive quarter.
Referral and Provider Network Growth
Referring provider network added 430 new providers in Q4 (+25% YoY) and over 1,300 new referrers in 2025; field teams completed >47,000 physician outreach activities and Q4 referrals exceeded 2,300 (+46% YoY).
Greenbrook Rollouts and SPRAVATO Adoption
SPRAVATO rollout nearly complete with 84 clinics providing treatment; SPRAVATO increased as a share of treatments (~30% early 2025 to ~35% by year-end), contributing materially to clinic growth and recurring maintenance revenue.
Commercial Programs and Partnerships Showing Traction
Better Me Provider program had 420+ active sites (plus ~100 in qualification), connecting >66,000 patients since inception; Provider Connection launched with 400+ educational meetings and 210+ new referral sites.
Improved Cash Flow and Balance Sheet Progress
Positive operating cash flow in Q4: cash provided by operations +$0.9M; operating cash burn improved every quarter in 2025 (from -$17.0M in Q1 to +$0.9M in Q4). Cash balance as of 12/31/2025 was $34.1M (including $6.0M restricted).
Profitability Trajectory and Expense Discipline
Q4 net loss narrowed to $7.2M ($0.10/sh) vs. $12.7M prior year; Q4 EBITDA improved to -$4.3M vs -$11.0M prior year. Management expects operating expense run-rate to fall below $100M by Q4 2026 and operating cash flow to be positive in H2 2026.
Strategic Pipeline Opportunity (COMP360 / Psilocybin)
Collaboration with COMPASS on COMP360 psilocybin positions Greenbrook to potentially commercialize an NDA-stage REMS therapy; COMPASS Phase 3 results reported durable benefits through 26 weeks with potential FDA decision by year-end, and Greenbrook expects limited incremental infrastructure lift due to SPRAVATO experience.
STIM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
STIM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 17, 2026 | $1.36 | $1.23 | -9.93% |
Nov 04, 2025 | $2.77 | $2.87 | +3.61% |
Aug 05, 2025 | $4.66 | $4.54 | -2.58% |
May 06, 2025 | $4.50 | $4.50 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Neuronetics Inc (STIM) report earnings?
Neuronetics Inc (STIM) is schdueled to report earning on May 12, 2026, Before Open (Confirmed).
What is Neuronetics Inc (STIM) earnings time?
Neuronetics Inc (STIM) earnings time is at May 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is STIM EPS forecast?
STIM EPS forecast for the fiscal quarter 2026 (Q1) is -0.17.